Search results for CONTACT COLASHIP.SHOP TO
Results found
Displaying items 301 - 310 of 361 in total
-
Export opportunity
Drugs
Conclusion of non-exclusive discount contracts according to §§ 130a para. 8/130c para. 1 SGB V for drugs with the active ingredient bexarotene (L01XF03) within…
-
Export opportunity
Drugs
Conclusion of non-exclusive discount contracts according to §§ 130a para. 8/130c para. 1 SGB V for drugs with the active ingredient formoterol and beclometason…
-
Export opportunity
Pharmaceuticals
Conclusion of non-exclusive discount agreements in accordance with Sections 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient h…
-
Export opportunity
Health and social care services
The subject of the open house procedure is the conclusion of non-exclusive agreements on the provision of care services in accordance with § 45 SGB XI in twelv…
-
Export opportunity
United states army research institute for the behavioral and social sciences (ari) broad agency announcement for basic, applied, and advanced scientific research
View Changes SOURCES SOUGHT NOTICE: REQUEST FOR WHITE PAPERS BAA TOPIC II A.2-8.a.2: Enhancing Job Classification and Assignment "Review of Army Aptitude Area …
-
Export opportunity
Pharmaceuticals
Conclusion of non-exclusive discount agreements in accordance with Sections 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient g…
-
Export opportunity
Pharmaceuticals
Conclusion of non-exclusive discount agreements pursuant to Sections 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient glatiram…
-
Export opportunity
Pharmaceuticals
Conclusion of non-exclusive discount agreements pursuant to Sections 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient methoxy-…
-
Export opportunity
Pharmaceuticals
Conclusion of non-exclusive discount agreements in accordance with Sections 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient s…
-
Export opportunity
Drugs
Conclusion of non-exclusive discount agreements pursuant to Sections 130a (8)/130c (1) SGB V for drugs with the active ingredient Natalizumab (L04AA23), s.c. d…